Collegium Pharmaceutical Inc

Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing medicines for people living with complex central nervous system and pain conditions. The company's ADHD portfolio includes JORNAY PM (methylphenidate HCl), an evening-dosed stimulant for ADHD, and AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a prodrug-based stimulant combining fast and long-acting components in a single capsule, acquired from Corium Therapeutics in May 2026 with patent protection through 2037. The company's pain portfolio consists of Belbuca (buprenorphine buccal film) for chronic pain, Xtampza ER (abuse-deterrent extended-release oxycodone), and the Nucynta Franchise (tapentadol), including authorized generic versions. Collegium employs formulation and delivery innovation across its product lines, with a unified commercial platform serving both neuropsychiatry/pediatric and pain management healthcare providers. The company trades on Nasdaq under the ticker COLL and had approximately $2.1 billion in total assets as of June 30, 2026, with significant intangible assets and goodwill from its acquisition strategy. Updated Aug 6, 2026